ClinicalTrials.gg
CompletedNCT05657197ENERGIZE-IBDUpdated Nov 13, 2026

The Effect of Intensive Physical Exercise on Fatigue and Quality of Life in Patients With Quiescent Inflammatory Bowel Disease

An interventional study of Exercise intervention and Usual care in Inflammatory Bowel Diseases, sponsored by Rijnstate Hospital. Completed at 4 sites in Netherlands. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Rijnstate Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Inflammatory Bowel Diseases with a site in Netherlands — 22 open to participants now, 28 under way, 7 of them phase 3. Inflammatory Bowel Diseases · Netherlands.

Enrollment
32nd of 61
100 · median 120
Started
2023
with 5 others
No phase
16 of 79
4 open now
Registered
58th of 79
by date

Among the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, this one is the 32nd largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2023, is one of 16 with no phase, and was the 58th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

22 of the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, or all of them as a file.
02

Study summary

In patients with inflammatory bowel diseases (IBD), characterized by relapsing intestinal inflammation, chronic fatigue is a burdensome and highly prevalent symptom. The aetiology is thought to be multifactorial, including complex interactions of psychological and physical factors such as immunological profiles and gut microbiota. Unfortunately, specific treatment strategies are currently lacking. Since fatigued patients have an impaired physical fitness and are less physically active than patients without fatigue, it is hypothesised that physical exercise might be an effective complementary treatment for patients with IBD suffering from fatigue. During a previous pilot cohort study, significant improvements in fatigue complaints and quality of life were observed following a personalised and intensive exercise program. In this study, a multicenter randomized controlled trial will be performed to further investigate this assumed beneficial effect of intensive physical exercise.

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • Fatigue
  • Exercise
  • Quality of life
  • IBD
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥1 year diagnosis of IBD, including Crohn's disease (CD), ulcerative colitis (UC) and IBD-unclassified (IBD-U), based on a combination of clinical, endoscopic, histologic and radiologic internationally accepted criteria;
  • Chronic fatigue complaints for at least 3 months;
  • Severe fatigue complaints as confirmed with a score of ≥11 on section I of the inflammatory bowel disease fatigue self-assessment scale (IBD-F);
  • Clinically quiescent IBD with a Harvey Bradshaw Index (HBI) \<5 for Crohn's disease patients or a Simple Colitis Clinical Activity Index (SCCAI) ≤2 for patients with ulcerative colitis or IBD-unclassified;
  • Faecal calprotectin \<100 μg/g;
  • Stable medication for at least 3 months before screening visit;
  • Patient is able and willing to provide written ;
  • Patient is able/commitment to make a time investment to complete the intervention program (one hour training 3x/week during 12 weeks) or, after randomisation, willing to participate in the control group;
  • Patient is aged between 18 and 60 years.

Exclusion criteria

Exclusion Criteria:

  • Performing moderate-vigorous intensity exercise (i.e. swimming, running, cycling) more than once and/or >90 minutes per week in the past 3 months;
  • Surgery within the past 6 months or planned surgery within 12 months after the screening visit;
  • Participation in another intervention study;
  • Pregnant at the moment of the screening visit or planning pregnancy within 12 months after the screening;
  • Confirmed diagnosis of other causes of fatigue complaints, such as thyroid dysfunction, liver or renal failure, anaemia, folate-, iron-, vitamin B12- or D deficiency.
  • Comorbidities that could be confounders for fatigue, such as (COPD), heart failure, active , long/Post-COVID and patients under treatment for a psychiatric disorder (i.e. depression/anxiety)
  • Comorbidities that prevent safe participation in the exercise program/cardiorespiratory fitness test including;

    • Very high risk of cardiovascular disease
    • Uncontrolled diabetes mellitus with > 65 mmol/l.
    • Cardiovascular disease (i.e. acute myocardial infarct, unstable angina, uncontrolled arrhythmias, aortic stenosis, stenotic valvular heart disease, untreated arterial hypertension (>200 mmHg systolic, >120 mmHg diastolic))
    • Acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e. infection, thyrotoxicosis)
    • Uncontrolled asthma
    • Pulmonary oedema
    • Significant pulmonary hypertension
    • Acute pulmonary embolus or pulmonary infarction
    • Room air desaturation at rest \<85% (exercise with supplemental O2)
    • Respiratory failure
    • Electrolyte abnormalities (sodium, potassium, calcium, magnesium)
    • Mental impairment leading to inability to cooperate
    • Orthopaedic impairment that compromise exercise performance
    • ≥35
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Intervention (exercise) group

    The patients in the intervention group will follow a personalised and intensive exercise program.

    Behavioral: Exercise intervention

  • Other
    Control group

    The patients in the control group will receive usual care.

    Other: Usual care

Interventions

  • BehavioralExercise intervention

    A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.

  • OtherUsual care

    Usual care, including general advice concerning chronic fatigue.

06

What researchers measure

Primary outcomes

  1. Change in fatigue (IBD-F), post-intervention

    Mean change in fatigue, measured with the inflammatory bowel disease fatigue self-assessment scale (IBD-F) 0-140 with higher scores indicating worse fatigue, in the intervention group compared to the control group.

    Time frame: 3 months (post-intervention)

  2. Change in quality of life (IBDQ), post-intervention

    Mean change in quality of life, measured with the inflammatory bowel disease questionnaire (IBDQ) 32-224 with higher scores representing better quality of life, in the intervention group compared to the control group.

    Time frame: 3 months (post-intervention)

Secondary outcomes

  1. Long-term change in fatigue (IBD-F)

    Mean change in fatigue, as measured after 6- and 12-months using the IBD-F, in the intervention group compared to the control group

    Time frame: 6- and 12-months

  2. Long-term change in quality of life (IBDQ)

    Mean change in quality of life, as measured after 6- and 12-months using the IBDQ, in the intervention group compared to the control group

    Time frame: 6- and 12-months

  3. Change in cardiorespiratory fitness (maximum oxygen uptake)

    Change in cardiorespiratory fitness (maximum oxygen uptake) of patients in the intervention group, assessed using Cardiopulmonary Exercise Testing (CPET).

    Time frame: 3 months (post-intervention)

  4. Change in cardiorespiratory fitness (maximum power)

    Change in cardiorespiratory fitness (maximum power) of patients in the intervention group, assessed using Cardiopulmonary Exercise Testing (CPET).

    Time frame: 3 months (post-intervention)

  5. Change in muscular strength

    Change in muscular strength of patients in the intervention group, assessed using one-repetition maximum (1-RM)

    Time frame: 3 months (post-intervention)

  6. Change in body composition (BMI)

    Change in body composition in the intervention group, as determined by body mass index (BMI).

    Time frame: 3 months (post-intervention)

  7. Change in body composition (body fat percentage)

    Change in body composition in the intervention group, as determined by body fat percentage measured using skinfold techniques

    Time frame: 3 months (post-intervention)

  8. Change in work absenteeism and presenteeism

    Change in work absenteeism and presenteeism in the intervention group compared to the control group, as measured by the Productivity Cost Questionnaire (iPCQ)

    Time frame: T= 3-, 6-, 9-, and 12-months

  9. Disease activity (FCP)

    Disease activity measured by change in faecal calprotectin (FCP), in both the intervention- and control group

    Time frame: T= 3-, 6-, 9-, and 12-months

  10. Disease activity (step-up therapy)

    Disease activity measured by step-up therapy rate in both the intervention- and control group

    Time frame: T= 3-, 6-, 9-, and 12-months

  11. Disease activity (exacerbation rate)

    Disease activity measured by exacerbation rate in both the intervention- and control group

    Time frame: T= 3-, 6-, 9-, and 12-months

  12. Change in sleep quality

    Self-reported differences in sleep quality in the intervention group compared to the control group, using the Pittsburgh Sleep Quality Index (PSQI), 0-21 with higher scores indicating worse sleep quality.

    Time frame: T= 3-, 6-, 9-, and 12-months

  13. Change in anxiety and depression symptoms

    Mean change in anxiety and depression symptoms in the intervention group compared to the control group, measured using the Hospital Anxiety and Depression Scale (HADS) questionnaire, each subscale 0-21 higher scores indicating worse symptoms

    Time frame: T= 3-, 6-, 9-, and 12-months

  14. Targeted cost-utility analysis

    Targeted economic evaluation of the intervention using a targeted cost-utility analysis from a societal perspective including intervention costs, medical consumption costs and productivity loss. Effectiveness of the intervention will be determined using the mean Difference of quality adjusted life years (QALYs) between de intervention and control group, based on the designated EQ-5D-5L questionnaire.

    Time frame: 12 months

  15. Exploratory outcome measurements (immunological profiles)

    Differences in the immunological profiles (i.e. pro- and anti-inflammatory cytokines and soluble receptors, such as IL-10, IL-6, IFN-ɣ) in the intervention group compared to the control group

    Time frame: 3 months (post-intervention)

  16. Exploratory outcome measurements (gut microbiota)

    Differences in the gut microbiota diversity and composition in the intervention group compared to the control group using 16SrRNA sequencing.

    Time frame: 3 months (post-intervention)

  17. Exploratory outcome measurements (biogenic amines)

    Differences in the concentration of biogenic amines in the intervention group compared to the control group.

    Time frame: 3 months (post-intervention)

07

Study locations

4 sites
08

References and documents

Publications

  • van Erp LW, Roosenboom B, Komdeur P, Dijkstra-Heida W, Wisse J, Horjus Talabur Horje CS, Liem CS, van Cingel REH, Wahab PJ, Groenen MJM. Improvement of Fatigue and Quality of Life in Patients with Quiescent Inflammatory Bowel Disease Following a Personalized Exercise Program. Dig Dis Sci. 2021 Feb;66(2):597-604. doi: 10.1007/s10620-020-06222-5. Epub 2020 Apr 1. PubMed 32239380 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Jul 2025, 29 months.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 29 months is close to that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2024 → Jul 2025 and completion Dec 2025 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2022
First posted
Dec 20, 2022
StartActual
Jan 10, 2023
Primary completionActual
Jul 7, 2025was Dec 2024
CompletionActual
Apr 4, 2026was Dec 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 Netherlands)
  • Jeroen Bosch Hospital · 's-Hertogenbosch, Netherlands
  • Canisius Wilhelmina Hospital · Nijmegen, Netherlands
Show 1 removed
  • Jeroen Bosch Hospital · Den Bosch, Netherlands
Nov 13, 2026
Primary completion
Dec 2024→Jul 7, 2025 (actual)
Nov 13, 2026
Study completion
Dec 2025→Apr 4, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    2 sites added, 1 site removed
    Show 2 added (2 Netherlands)
    • Jeroen Bosch Hospital · 's-Hertogenbosch, Netherlands
    • Canisius Wilhelmina Hospital · Nijmegen, Netherlands
    Show 1 removed
    • Jeroen Bosch Hospital · Den Bosch, Netherlands
    Primary completion Dec 2024→Jul 7, 2025 (now actual)
    Study completion Dec 2025→Apr 4, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05657197
Lead sponsor
Rijnstate Hospital
Collaborators
Dutch Digestive Diseases Foundation, Sport Medisch Centrum Papendal, FormUpgrade, Arnhem, Sport Medisch Centrum, Jeroen Bosch Ziekenhuis
Responsible party
Sponsor
First posted
Dec 20, 2022
Start date
Jan 10, 2023
Primary completion
Jul 7, 2025
Completion
Apr 4, 2026
Last update
Nov 13, 2026

Study contacts

Dr. M.J.M. Groenen, MD, PhD
principal investigator · Gastroenterology department, Rijnstate Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion